Appili Therapeutics Inc. (TSX:APLI)
Canada · Delayed Price · Currency is CAD 0.0100
0.00 (0.00%)
Sep 3, 2026, 4:10 PM EST
Appili Therapeutics Balance Sheet
Financials in millions CAD. Fiscal year is April - March.
Millions CAD. Fiscal year is Apr - Mar.
Assets
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 0.14 | 0.04 | 1.23 | 0.09 | 2.47 | 6.66 |
Cash & Short-Term Investments | 0.14 | 0.04 | 1.23 | 0.09 | 2.47 | 6.66 |
Cash Growth | -87.67% | -96.74% | 1199.83% | -96.17% | -63.00% | -58.67% |
Other Receivables | 0.96 | 1.8 | 1.67 | 1.17 | 0.42 | 1.39 |
Receivables | 0.96 | 1.8 | 1.67 | 1.17 | 0.42 | 1.39 |
Prepaid Expenses | 0.19 | 0.12 | 0.11 | 0.19 | 0.23 | 0.18 |
Total Current Assets | 1.29 | 1.96 | 3.01 | 1.46 | 3.12 | 8.24 |
Property, Plant & Equipment | 0.01 | 0.01 | 0.02 | 0.03 | 0.01 | 0.04 |
Total Assets | 1.3 | 1.97 | 3.03 | 1.49 | 3.13 | 8.28 |
Liabilities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 6.48 | 6.03 | 4.02 | 4.11 | 2.75 | 6.38 |
Accrued Expenses | 0.27 | 0.28 | 0.09 | 0.08 | 0.08 | 0.07 |
Current Portion of Long-Term Debt | 12.69 | 12.26 | 11.56 | 7.31 | 0.11 | 0.1 |
Current Income Taxes Payable | 0.07 | 0.06 | 0.03 | 0.05 | 0.04 | - |
Other Current Liabilities | 0.18 | - | - | - | - | - |
Total Current Liabilities | 19.68 | 18.63 | 15.69 | 11.54 | 2.98 | 6.67 |
Long-Term Debt | 0.64 | 0.67 | 0.74 | 0.88 | 7.55 | 4.88 |
Total Liabilities | 20.32 | 19.3 | 16.43 | 12.42 | 10.53 | 11.55 |
Shareholders' Equity
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 42.49 | 42.49 | 42.32 | 42.32 | 42.32 | 39.65 |
Additional Paid-In Capital | 15.49 | 15.48 | 14.82 | 12.87 | 6.41 | 5.01 |
Retained Earnings | -77.66 | -75.96 | -71.72 | -69.09 | -65.31 | -56.07 |
Comprehensive Income & Other | 0.65 | 0.65 | 1.18 | 2.98 | 9.18 | 8.13 |
Shareholders' Equity | -19.02 | -17.33 | -13.4 | -10.92 | -7.4 | -3.27 |
Total Liabilities & Equity | 1.3 | 1.97 | 3.03 | 1.49 | 3.13 | 8.28 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 13.33 | 12.94 | 12.29 | 8.18 | 7.67 | 4.98 |
Net Cash (Debt) | -13.19 | -12.9 | -11.07 | -8.09 | -5.2 | 1.69 |
Net Cash Growth | - | - | - | - | - | -88.83% |
Net Cash Per Share | -0.10 | -0.10 | -0.09 | -0.07 | -0.05 | 0.03 |
Filing Date Shares Outstanding | 132.37 | 132.37 | 121.27 | 121.27 | 121.27 | 121.27 |
Total Common Shares Outstanding | 132.37 | 132.37 | 121.27 | 121.27 | 121.27 | 71.27 |
Working Capital | -18.39 | -16.67 | -12.68 | -10.08 | 0.14 | 1.57 |
Book Value Per Share | -0.14 | -0.13 | -0.11 | -0.09 | -0.06 | -0.05 |
Tangible Book Value | -19.02 | -17.33 | -13.4 | -10.92 | -7.4 | -3.27 |
Tangible Book Value Per Share | -0.14 | -0.13 | -0.11 | -0.09 | -0.06 | -0.05 |
Machinery | - | - | - | - | 0.06 | 0.13 |